Repligen (RGEN) Tops Q2 EPS by 9c ; Offers Guidance

Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.54, $0.09 better than the analyst estimate of $0.45. Revenue for the quarter came in at $204 million versus the consensus estimate of $201.47 million.

Outlook:-
FY 2026 EPS between $2.03-$2.09 vs consensus $2.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
• LendingTree (TREE) 2877 contracts of October 30 calls trade, share price up 4.6%
• Fidelity National Financial (FNF) spreader of 3K contracts of October 35, October 45, November 30 and November 35 puts